Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Revenue of Advaxis, Inc. (ADXS)
Revenue in 2023 (TTM): $13 K
According to Advaxis, Inc.'s latest financial reports the company's current revenue (TTM) is $13 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Advaxis, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $13 K | $ | $-35,869,000 | $-51,984,000 | $-48,072,000 |
| 2022 | $250 K | $-64,000 | $-15,776,000 | $-14,309,000 | $-14,359,000 |
| 2021 | $3.24 M | $-468,000 | $-18,766,000 | $-17,812,000 | $-17,862,000 |
| 2020 | $253 K | $-1,032,000 | $-24,394,000 | $-26,419,000 | $-26,469,000 |
| 2019 | $2.33 M | $1.05 M | $-17,561,000 | $-17,486,000 | $-17,792,000 |
| 2018 | $6.06 M | $6.06 M | $-72,278,000 | $-66,465,000 | $-66,515,000 |
| 2017 | $12.03 M | $12.03 M | $-97,427,612 | $-97,838,084 | $-93,435,402 |
| 2016 | $3.99 M | $3.99 M | $-76,025,101 | $-76,091,855 | $-73,556,230 |
| 2015 | $ | $-265,390 | $-48,356,317 | $-48,640,467 | $-47,031,118 |
| 2014 | $1000 K | $1000 K | $-19,292,733 | $-18,882,194 | $-16,525,314 |
| 2013 | $ | $ | $-18,041,169 | $-20,712,016 | $-19,986,826 |
| 2012 | $ | $ | $-12,172,993 | $-12,416,474 | $-12,069,687 |
| 2011 | $ | $ | $-13,781,332 | $-8,495,212 | $-8,115,740 |
| 2010 | $508.48 K | $508.48 K | $-7,787,067 | $-11,091,178 | $-10,812,200 |
| 2009 | $29.69 K | $29.69 K | $-4,875,844 | $7.22 K | $929.24 K |
| 2008 | $65.74 K | $65.74 K | $-5,301,068 | $-5,405,155 | $-5,416,418 |
| 2007 | $154.2 K | $154.2 K | $-7,094,942 | $-1,847,260 | $-2,454,453 |
| 2006 | $431.96 K | $431.96 K | $-193,696 | $-5,760,444 | $-6,197,744 |
| 2005 | $552.87 K | $552.87 K | $-1,801,359 | $-1,805,789 | $-1,805,789 |
| 2004 | $116.41 K | $116.41 K | $-518,143 | $-533,847 | $-538,076 |
| 2003 | $ | $ | $-10,000 | $-10,000 | $-10,000 |
| 2002 | $ | $ | $-10,000 | $-10,000 | $-10,000 |